Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

875
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
875
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

295
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
295
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

35
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic health and cardiovascular outcomes in treated hypertension: a secondary analysis of SPRINT.

Clinical hypertension·2026
Same author

Incidence and risk factors for aortic dissection in a community-based cohorts: The Atherosclerosis Risk in Communities (ARIC) and Multi-Ethnic Study of Atherosclerosis (MESA) studies.

American journal of preventive cardiology·2026
Same author

Prevention of atherosclerotic coronary artery disease in tactical athletes.

American journal of preventive cardiology·2026
Same author

Beyond therapeutic maximalism: Prioritization and personalization in preventive therapies.

Progress in cardiovascular diseases·2026
Same author

Response to: "Absolute cardiovascular risk: the missing denominator in Lp(a)-guided aspirin therapy in primary prevention".

European journal of preventive cardiology·2026
Same author

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026

Related Experiment Video

Updated: Sep 14, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.5K

Current Clinical Trials for Treating Elevated Lipoprotein(a).

Chris De Los Reyes1, Rishi Raj Rikhi2, Sean Doherty2

  • 1Department of Public Health Sciences, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, USA.

Current Cardiovascular Risk Reports
|July 24, 2025
PubMed
Summary

New therapies targeting lipoprotein(a) [Lp(a)] show promise for reducing cardiovascular risk. Investigational agents, including siRNA, ASO, and small molecule inhibitors, are in clinical trials with favorable safety and efficacy. Further research will confirm long-term benefits.

Keywords:
Lipoprotein(a)atherosclerotic cardiovascular diseasecalcific aortic stenosisdyslipidemiashort interfering RNA

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Related Experiment Videos

Last Updated: Sep 14, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.5K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Genetics

Background:

  • Elevated lipoprotein(a) [Lp(a)] is a significant, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS).
  • Lp(a) has historically been a challenging target for drug therapy, despite its established role in cardiovascular risk.
  • Developing targeted therapies to lower Lp(a) serum concentrations is a key goal for improving patient outcomes.

Purpose of the Study:

  • To review investigational agents currently in clinical trials for lowering Lp(a).
  • To highlight key differences among these agents, including dosing and administration routes.
  • To inform on factors influencing medication uptake and retention in diverse patient populations.

Main Methods:

  • Review of clinical trial data for investigational Lp(a)-lowering agents.
  • Analysis of drug classes including small interfering RNA (siRNA), antisense oligonucleotides (ASO), small molecule inhibitors, CETP inhibitors, and gene-editing therapies.
  • Comparison of administration routes (subcutaneous, oral) and dosing intervals.

Main Results:

  • Multiple agents (siRNA, ASO, oral small molecule) are in clinical trials, demonstrating notable Lp(a) reductions.
  • Favorable tolerability and safety profiles have been observed in early-stage trials.
  • A CETP inhibitor and gene-editing therapies are also under investigation, with varying stages of development.

Conclusions:

  • Promising therapeutic options for lowering Lp(a) are emerging, potentially addressing a long-standing unmet need in cardiovascular medicine.
  • Phase 3 trials are critical to validate the long-term safety and efficacy of these agents.
  • Optimizing patient selection and treatment strategies will be vital for maximizing the benefit of these novel therapies for ASCVD prevention.